Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities

被引:29
作者
Chu, Chia-Yu [1 ,2 ]
Chen, Kuan-Yu [2 ,3 ]
Chang, John Wen-Cheng [4 ]
Wei, Yu-Feng [5 ,6 ]
Lee, Chih-Hung [7 ,8 ]
Wang, Wei-Ming [9 ,10 ]
机构
[1] Natl Taiwan Univ Hosp, Dept Dermatol, 7 Chung Shan South Rd, Taipei 10002, Taiwan
[2] Natl Taiwan Univ, Coll Med, 7 Chung Shan South Rd, Taipei 10002, Taiwan
[3] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan
[4] Chang Gung Univ, Chang Gung Mem Hosp Linkou, Coll Med, Dept Internal Med,Div Hematol Oncol, Taoyuan, Taiwan
[5] I Shou Univ, Dept Internal Med, Kaohsiung, Taiwan
[6] E Da Hosp, Kaohsiung, Taiwan
[7] Kaohsiung Chang Gung Mem Hosp, Dept Dermatol, Kaohsiung, Taiwan
[8] Chang Gung Univ, Coll Med, Taoyuan, Taiwan
[9] Triserv Gen Hosp, Dept Dermatol, Taipei, Taiwan
[10] Natl Def Med Ctr, Taipei, Taiwan
关键词
consensus; diagnosis; epidermal growth factor receptor; skin toxicities; tyrosine kinase inhibitors; CELL LUNG-CANCER; OPEN-LABEL; 1ST-LINE TREATMENT; ADVERSE EVENTS; PHASE-III; CARBOPLATIN-PACLITAXEL; CUTANEOUS TOXICITIES; TREATMENT STRATEGIES; GEFITINIB; ERLOTINIB;
D O I
10.1016/j.jfma.2017.03.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/Purpose: This report describes the 2016 consensus of the Taiwanese Dermatological Association (TDA) regarding the definition, classification, diagnosis, prevention, and management of skin toxicities resulting from treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). This consensus is distributed to practices throughout Taiwan to provide recommendations for the diagnosis and treatment of such skin toxicities in order to improve the quality of life of patients undergoing EGFR-TKI treatment. The consensus thus serves as an important reference for dermatologists and other interested clinicians, such as oncologists, throughout Taiwan. Methods: All the consensus contents were voted on by the participating experts, with approval by no less than 75% required for inclusion. Results: The consensus provides a comprehensive overview of EGFR-TKI skin toxicities, including recent advances in identifying their causes and the processes by which they develop. Conclusion: All the consensus meeting attendees agreed that there are several major EGFR-TKI-related skin toxicities, including acneiform rash (i.e., papulopustular rash), xeroderma, pruritus, paronychia, stomatitis, mucositis, and hair changes (such as hair loss, slowed hair growth, and trichomegaly). The experts were also generally unanimous in their voting on the specific definitions, onset times, and care suggestions for each of those skin toxicities. Furthermore, the recommended treatment algorithms for the various skin toxicities were ultimately approved by 100% (15/15) of the consensus attendees. Copyright (C) 2017, Formosan Medical Association. Published by Elsevier Taiwan LLC.
引用
收藏
页码:413 / 423
页数:11
相关论文
共 33 条
  • [1] [Anonymous], J ONCOL NURS S
  • [2] [Anonymous], J CLIN ONCOL S
  • [3] [Anonymous], MASCC EGFR INH SKIN
  • [4] Arriola E, 2015, FUTURE ONCOL, V11, P267, DOI [10.2217/FON.14.214, 10.2217/fon.14.214]
  • [5] Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK
    Califano, R.
    Tariq, N.
    Compton, S.
    Fitzgerald, D. A.
    Harwood, C. A.
    Lal, R.
    Lester, J.
    McPhelim, J.
    Mulatero, C.
    Subramanian, S.
    Thomas, A.
    Thatcher, N.
    Nicolson, M.
    [J]. DRUGS, 2015, 75 (12) : 1335 - 1348
  • [6] A patient with acantholytic pustular purpuric eruption due to gefitinib successfully treated with systemic antibiotics
    Chen, Kai-Lung
    Cho, Yung-Tsu
    Yang, Che-Wen
    Sheen, Yi-Shuan
    Liau, Jau-Yu
    Chu, Chia-Yu
    [J]. DERMATOLOGICA SINICA, 2016, 34 (03) : 166 - 167
  • [7] Comparison of Skin Toxic Effects Associated With Gefitinib, Erlotinib, or Afatinib Treatment for Non-Small Cell Lung Cancer
    Chen, Kai-Lung
    Lin, Chia-Chi
    Cho, Yung-Tsu
    Yang, Che-Wen
    Sheen, Yi-Shuan
    Tsai, Hsiao-En
    Chu, Chia-Yu
    [J]. JAMA DERMATOLOGY, 2016, 152 (03) : 340 - 342
  • [8] Treatment strategies of epidermal growth factor receptor inhibitor-induced skin toxicities: pre-emptive or reactive?
    Cho, Yung-Tsu
    Chen, Kai-Lung
    Chu, Chia-Yu
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2016, 4 (16)
  • [9] Taiwanese Dermatological Association consensus for the management of atopic dermatitis
    Chu, Chia-Yu
    Lee, Chi-Hung
    Shih, I-Hsin
    Chen, Hsiu-Chin
    Huang, Po-Han
    Yang, Chin-Yi
    Wang, Wen-Jen
    Chen, Yi-Ju
    Sheu, Hamm-Ming
    Wang, Wei-Ming
    Lee, Woan-Ruoh
    Lo, Yuan-Hsin
    Dai, Yang-Shia
    Wang, Li-Fang
    Tsai, Tsen-Fang
    Yang, Chih-Hsun
    [J]. DERMATOLOGICA SINICA, 2015, 33 (04) : 220 - 230
  • [10] Taiwanese Dermatological Association consensus for the definition, classification, diagnosis, and management of urticaria
    Chung, Wen-Hung
    Chu, Chia-Yu
    Huang, Yu-Huei
    Wang, Wei-Ming
    Yang, Chih-Hsun
    Tsai, Tsen-Fang
    [J]. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2016, 115 (11) : 968 - 980